Predicting responses to chemotherapy in the context that matters - the patient

ABSTRACT Guided by the belief that the most important setting for understanding tumor response to drugs is the human patient, we developed a technology called CIVO. CIVO enables analysis of up to 8 therapies simultaneously in a patient's tumor, without inducing systemic toxicity and while maintaining the integrity of the native tumor microenvironment.

• Publication year

  2015

• Venue

  Molecular & Cellular Oncology

• Publication date

  2015-06-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/23723556.2015.1057315PMID 27308571PMCID 4845209
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A technology platform to assess multiple cancer agents simultaneously within a patient’s tumor

  2015cited by this paper
• Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution

  2014cited by this paper
• Lymphoid neoplasm incidence by WHO subtype in Australia 1982–2006

  2014cited by this paper
• Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial.

  2013cited by this paper
• When are "positive" clinical trials in oncology truly positive?

  2011cited by this paper
• Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer

  2009cited by this paper
• Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

  2007cited by this paper
• Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

  2004cited by this paper

• Nanotechnology for Diagnosis, Imaging, and Treatment of Head and Neck Cancer

  2021cites this paper
• Trial Watch: experimental TLR7/TLR8 agonists for oncological indications

  2020cites this paper